Literature DB >> 14971563

Laser and proton radiation to reduce uveal melanoma-associated exudative retinal detachments.

Devron H Char1, Riley Bove, Theodore L Phillips.   

Abstract

PURPOSE: To assess whether laser-induced hyperthermia in conjunction with proton irradiation of choroidal melanoma may more rapidly decrease exudative retinal detachments.
DESIGN: Case-control study.
METHODS: This was a single-center prospective phase 1 study of choroidal melanoma patients with exudative retinal detachments. These tumors did not overhang the optic disc, involve the fovea, or have greater than 40% involvement of the ciliary body. Patients were treated with laser-induced hyperthermia and proton radiation; results were compared with those of similar patients treated at the same institution with only proton radiation. Patients were followed up in an identical manner for loss of subretinal fluid, visual acuity change, and visual field alterations.
RESULTS: All 11 patients treated with combined laser and proton therapy had resorption of subretinal fluid with a mean duration of retinal detachment of 193 days, compared with 263 days in the group treated with only proton therapy (P<.04). At 1 year, visual acuity was similar in both groups.
CONCLUSIONS: Combined laser-induced hyperthermia and proton radiation may dissipate exudative detachments more rapidly than radiation alone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14971563      PMCID: PMC1358974     

Source DB:  PubMed          Journal:  Trans Am Ophthalmol Soc        ISSN: 0065-9533


  22 in total

1.  Transpupillary thermotherapy as primary treatment for small choroidal melanomas.

Authors:  D M Robertson; H Buettner; S R Bennett
Journal:  Trans Am Ophthalmol Soc       Date:  1999

2.  Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations.

Authors:  Carol L Shields; Jerry A Shields; Noel Perez; Arun D Singh; Jacqueline Cater
Journal:  Ophthalmology       Date:  2002-02       Impact factor: 12.079

Review 3.  Synergistic cell-killing effect of a combination of hyperthermia and heavy ion beam irradiation: in expectation of a breakthrough in the treatment of refractory cancers (review).

Authors:  Masahiro Imamura; Satoshi Sawada; Mika Kasahara-Imamura; Keizo Harima; Kazuki Harada
Journal:  Int J Mol Med       Date:  2002-01       Impact factor: 4.101

4.  Additional cell damage after transpupillary thermotherapy in choroidal malignant melanoma.

Authors:  J Kociecki; W Biczysko; H G Korver; J E Keunen; K Pecold
Journal:  Melanoma Res       Date:  2001-10       Impact factor: 3.599

5.  [Transpupillary thermotherapy combined with 106Ru as a method of managing choroidal melanoma].

Authors:  M Starzycka; B Romanowska-Dixon; J Słomska; U Szpakowicz
Journal:  Klin Oczna       Date:  2000

6.  Exudative retinal detachment from malignant uveal melanoma: predictors and prognostic significance.

Authors:  T Kivelä; S Eskelin; T Mäkitie; P Summanen
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-08       Impact factor: 4.799

7.  Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma.

Authors:  E Egger; A Schalenbourg; L Zografos; L Bercher; T Boehringer; L Chamot; G Goitein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-09-01       Impact factor: 7.038

8.  [Prospective nonrandomised analysis of "Sandwich Therapy" for malignant melanoma of the choroid].

Authors:  Bernhard M Stoffelns; Joachim Kutzner; Kilian Schöpfer; Martine Frising
Journal:  Klin Monbl Augenheilkd       Date:  2002-04       Impact factor: 0.700

9.  Clinicopathologic findings in recurrent choroidal melanoma after transpupillary thermotherapy.

Authors:  C E Diaz; A Capone; H E Grossniklaus
Journal:  Ophthalmology       Date:  1998-08       Impact factor: 12.079

10.  Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients.

Authors:  Carol L Shields; Jacqueline Cater; Jerry A Shields; Aning Chao; Hatem Krema; Miguel Materin; Luther W Brady
Journal:  Arch Ophthalmol       Date:  2002-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.